JP2022525071A5 - - Google Patents

Info

Publication number
JP2022525071A5
JP2022525071A5 JP2021553837A JP2021553837A JP2022525071A5 JP 2022525071 A5 JP2022525071 A5 JP 2022525071A5 JP 2021553837 A JP2021553837 A JP 2021553837A JP 2021553837 A JP2021553837 A JP 2021553837A JP 2022525071 A5 JP2022525071 A5 JP 2022525071A5
Authority
JP
Japan
Prior art keywords
cancer
amino acid
cdrs
domain
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021553837A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525071A (ja
JP7581225B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/021783 external-priority patent/WO2020185722A2/en
Publication of JP2022525071A publication Critical patent/JP2022525071A/ja
Publication of JP2022525071A5 publication Critical patent/JP2022525071A5/ja
Application granted granted Critical
Publication of JP7581225B2 publication Critical patent/JP7581225B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021553837A 2019-03-13 2020-03-10 Ctla-4遮断剤とpd-1遮断剤とを含む抗癌併用療法 Active JP7581225B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962817749P 2019-03-13 2019-03-13
US62/817,749 2019-03-13
PCT/US2020/021783 WO2020185722A2 (en) 2019-03-13 2020-03-10 Anti-cancer combination therapies comprising ctla-4 and pd-1 blocking agents

Publications (3)

Publication Number Publication Date
JP2022525071A JP2022525071A (ja) 2022-05-11
JP2022525071A5 true JP2022525071A5 (cg-RX-API-DMAC7.html) 2023-03-24
JP7581225B2 JP7581225B2 (ja) 2024-11-12

Family

ID=72426465

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021553837A Active JP7581225B2 (ja) 2019-03-13 2020-03-10 Ctla-4遮断剤とpd-1遮断剤とを含む抗癌併用療法

Country Status (11)

Country Link
US (2) US12358986B2 (cg-RX-API-DMAC7.html)
EP (1) EP3937979A4 (cg-RX-API-DMAC7.html)
JP (1) JP7581225B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210141539A (cg-RX-API-DMAC7.html)
CN (1) CN113631189B (cg-RX-API-DMAC7.html)
AU (1) AU2020234785B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021017892A8 (cg-RX-API-DMAC7.html)
CA (1) CA3132198A1 (cg-RX-API-DMAC7.html)
MA (1) MA55316A (cg-RX-API-DMAC7.html)
MX (1) MX2021010997A (cg-RX-API-DMAC7.html)
WO (1) WO2020185722A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102986821B1 (ko) 2020-04-22 2026-07-06 머크 샤프 앤드 돔 엘엘씨 인터류킨-2 수용체 베타 감마c 이량체에 대해 편향되고 비펩티드성 수용성 중합체에 접합된 인간 인터류킨-2 접합체
TW202241932A (zh) * 2020-12-23 2022-11-01 美商默沙東藥廠 用於治療自體免疫及發炎性疾病之il-2突變蛋白
EP4286520A4 (en) * 2021-01-29 2025-04-16 Minghui Pharmaceutical (Hangzhou) Limited Antigen-binding protein and use thereof
IL307494A (en) * 2021-04-14 2023-12-01 Akeso Pharmaceuticals Inc Use of antibody in anti-tumor treatment
TWI903067B (zh) * 2021-04-21 2025-11-01 中國商和鉑醫藥(上海)有限責任公司 結合ctla-4的抗體及其用途
KR20230110141A (ko) 2022-01-14 2023-07-21 영남대학교 산학협력단 PD-L1 단백질에 특이적으로 결합하는 Fab 단편 및 이의 용도
EP4522654A1 (en) * 2022-05-12 2025-03-19 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
KR20260056175A (ko) * 2023-08-21 2026-04-24 아게누스 인코포레이티드 Ctla-4 저해제와 pd-1 저해제의 병용을 이용한 결장직장암의 치료 방법
WO2025211692A1 (ko) * 2024-04-02 2025-10-09 (주)에트노바테라퓨틱스 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트
WO2025240670A2 (en) * 2024-05-15 2025-11-20 Abalytics Oncology, Inc. Anti-pd-1 antibodies and related binding molecules and methods and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
US8907065B2 (en) 2006-12-15 2014-12-09 Ablynx N.V. Polypeptides that modulate the interaction between cells of the immune system
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
CA2698419C (en) 2007-09-07 2019-11-12 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
US20130108623A1 (en) 2010-03-29 2013-05-02 Zymeworks Inc Antibodies with Enhanced or Suppressed Effector Function
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
SMT201900242T1 (it) 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
SG11201509566RA (en) 2013-05-20 2015-12-30 Genentech Inc Anti-transferrin receptor antibodies and methods of use
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
JP2017515859A (ja) 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 抗pd−1抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
ES2826566T3 (es) 2014-11-21 2021-05-18 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas
US10196445B1 (en) 2015-03-17 2019-02-05 Bristol-Myers Squibb Company Ipilimumab variant with enhanced ADCC
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
IL300122A (en) 2015-11-18 2023-03-01 Merck Sharp ַ& Dohme Llc Substances that bind to PD1 and/or LAG3
CN108473565B (zh) 2015-11-18 2022-05-27 默沙东公司 Ctla4结合剂
US10544222B2 (en) 2015-11-18 2020-01-28 Merck Sharp & Dohme Corp. PD1/CTLA4 binders
US11072657B2 (en) * 2015-11-18 2021-07-27 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody
BR112018011029A2 (pt) 2016-01-08 2018-11-21 Hoffmann La Roche métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
CN110072890B (zh) 2016-11-03 2022-11-29 百时美施贵宝公司 可活化的抗ctla-4抗体及其用途
CN110505882A (zh) 2017-03-31 2019-11-26 默沙东公司 用pd-1的拮抗剂和抗ctla4抗体的组合治疗癌症的组合物和方法
CA3060695A1 (en) * 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
TWI799432B (zh) 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
CN119792515A (zh) * 2018-02-13 2025-04-11 默沙东有限责任公司 用抗pd-1抗体和抗ctla-4抗体治疗癌症的方法

Similar Documents

Publication Publication Date Title
US11718681B2 (en) Anti-SIRP α antibodies
US11851495B2 (en) TRAILR2 CDH17 binding molecules for the treatment of cancer
JP2021531764A5 (cg-RX-API-DMAC7.html)
CN115551889A (zh) 抗cd73抗体及其用途
JP2019500891A5 (cg-RX-API-DMAC7.html)
JP2019500892A5 (cg-RX-API-DMAC7.html)
JP2025506318A (ja) 抗tigit抗体と抗pd-1-抗vegfa二重特異性抗体を含有する医薬組成物及び使用
JP7581225B2 (ja) Ctla-4遮断剤とpd-1遮断剤とを含む抗癌併用療法
US20220204644A1 (en) Combination of her2 antibodies
JP2025517737A5 (cg-RX-API-DMAC7.html)
US12521446B2 (en) Anti-CEACAM5 antibody drug conjugates
US20240150480A1 (en) Binding molecules for the treatment of cancer
RU2021129575A (ru) Способы комбинированного лечения злокачественных новообразований, включающие средства, блокирующие ctla-4 и pd-1
JP2024508597A5 (cg-RX-API-DMAC7.html)
RU2024116190A (ru) Антитело против cd73 и его применение
IL321672A (en) Anti-pdl1/vegf antibodies and methods of use